Pharmafile Logo
Pharmafocus logo
Advanced Search

Abraxane

Showing 11 posts of 11 posts found.

dr_patrick_soon-shiong_14212355607

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

April 4, 2019
Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …

News
celgene_building

Celgene’s Abraxane combo flops in phase 3 cancer trials

March 14, 2019
Research and Development Abraxane, Celgene, clinical trials, pharma, trials

Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …

News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016
Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …

News
allergan

Allergan files ANDA for generic version of Celgene’s breast cancer treatment

March 18, 2016
Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic

Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …

News
celgene_1_02

Two Celgene cancer drugs approved in Ireland

March 1, 2016
Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid

Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …

News
Abraxane

NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’

September 17, 2015
Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer

NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …

News
Sam Pierce image

Celgene UK: market access is a complex business

December 15, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce

Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …

Feature
Celgene image

Celgene rebuffed by NICE over cancer drug

September 9, 2014
Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel

In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …

News
Abraxane image

Cancer treatment Abraxane gets EU nod

January 9, 2014
Sales and Marketing Abraxane, Cancer, Celgene, EU, pancreatic

Celgene’s cancer drug Abraxane has been approved by European regulators to treat patients with metastatic adenocarcinoma of the pancreas, or …

News

Celgene completes Abraxis takeover

October 15, 2010
Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology

Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …

News

Celgene

January 1, 2010
Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide

Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …

Feature

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023